Loading clinical trials...
Loading clinical trials...
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Myriad Genetic Laboratories, Inc.
NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
NCT07580196 · Prostate Cancer
NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Salt Lake City, Utah
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions